Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Insights, Epidemiology and Market Forecast 2016-2027
Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]
SOURCE Research and Markets
DUBLIN, Nov. 9, 2018 /PRNewswire/ —
The “Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Market Insights, Epidemiology and Market Forecast-2027′ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NMOSD in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of NMOSD from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Neuromyelitis Optica Spectrum Disorder (NMOSD) – Disease Understanding and Treatment Algorithm
The Neuromyelitis Optica Spectrum Disorder market report gives the thorough understanding of the Neuromyelitis Optica Spectrum Disorder by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuromyelitis Optica Spectrum Disorder in the US, Europe, and Japan.
Neuromyelitis Optica Spectrum Disorder Epidemiology
The Neuromyelitis Optica Spectrum Disorder epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report is segmented by prevalent population, gender- specific [Male and Female] and NMO-IgG Diagnosed Cases [NMO-IgG Seropositive and NMO-IgG Seronegative] and Clinical Characterization (Transverse Myelitis, Longitudinally extensive TM, Focal TM, Optic Neuritis, Unilateral ON, and Bilateral ON).
According to this research, the prevalent cases of NMOSD was 32,382 in 2016 in 7 MM and, is expected to increase during the study period i.e., 2016-2027. Among 7MM, United States account for highest prevalent cases of NMOSD with 16,000 prevalent cases in 2016.
Neuromyelitis Optica Spectrum Disorder Drug Chapters
This segment of the Neuromyelitis Optica Spectrum Disorder report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies.
Neuromyelitis Optica Spectrum Disorder Market Outlook
The Neuromyelitis Optica Spectrum Disorder market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
NMOSD market is expected to grow during the forecasted period of 2018-2027 owing to the launch of few drugs (presently in Phase III and Phase II). NMOSD therapeutics market has seen a 7MM sales of USD 145.1 million in 2016.
Neuromyelitis Optica Spectrum Disorder Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Key Topics Covered:
1. Key Insights
2. Neuromyelitis Optica Spectrum Disorder: Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2017
2.2. Total Market Share (%) Distribution of Neuromyelitis Optica Spectrum Disorder in 2027
3. Neuromyelitis Optica Spectrum Disorder: Disease Background and Overview
3.2. Signs and Symptoms
3.3. Clinical features of NMO/NMOSD
3.7. International consensus diagnostic criteria for Neuromyelitis Optica Spectrum Disorders
3.8. Neuroimaging and neurophysiologic testing
3.8.1. Considerations for AQP4-IgG serologic and another laboratory testing.
3.8.2. Pediatric NMOSD criteria
3.8.3. Monophasic NMOSD
3.8.4. Systemic autoimmunity associated with NMOSD.
3.8.6. Opticospinal MS
4. Epidemiology and Patient Population
4.1. Key Findings
5. 7MM Total Prevalent Patient Population of NMO/NMOSD
6. Country Wise-Epidemiology of NMO/NMOSD
7.1. Treatment Algorithm
7.1.1. Treatment of Acute Attacks
7.1.2. Preventive Treatment of Relapse
7.2. Treatment Guidelines Country wise
7.2.1. American College of Chest Physicians Task Force
7.2.2. The European Federation of Neurological Societies
8. Unmet Needs
9. Key Cross Competitors
10. Emerging Drugs
10.1. MEDI-551: Viela Bio
10.2. Satralizumab (SA237): Chugai Pharmaceutical/ Roche
10.3. Soliris: Alexion Pharma
11. Neuromyelitis Optica: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of NMO/NMOSD in 7MM
12. United States Market Outlook
12.1. United States Market Size
12.1.1. Total Market size of NMO/NMOSD
12.1.2. Market size of NMO/NMOSD based on Types
12.1.3. Market Size by Therapies
13. EU-5 Countries: Market Outlook
14. Japan: Market Outlook
15. Market Drivers
16. Market Barriers
- Viela Bio
- Chugai Pharmaceutical/ Roche
- Alexion Pharma
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/zbzpx9/global?w=5
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
©2017 PR Newswire. All Rights Reserved.